Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2021

01-02-2021 | Concise Research Report

Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs

Authors: So-Yeon Kang, MPH, MBA, Mariana P. Socal, MD, PhD, Ge Bai, PhD, CPA, Gerard F. Anderson, PhD

Published in: Journal of General Internal Medicine | Issue 2/2021

Login to get access

Excerpt

Independent charity patient assistance programs are funded by pharmaceutical companies to help eligible patients cover their out-of-pocket costs for prescription drugs.1 Pharmaceutical companies are prohibited from advertising or distributing information about off-label uses of their products but commonly suggest off-label uses in their direct-to-consumer advertisements for certain drugs.2, 3 Independent charity patient assistance programs had been prohibited from offering financial assistance for off-label uses until 2014,4 when the US Department of Health and Human Services relaxed the guidelines to allow these programs to cover less expensive drugs for off-label uses.5 The extent to which independent charity patient assistance programs have covered off-label uses of prescription drugs and the types of these covered drugs have not been examined. …
Literature
3.
go back to reference Klara K, Kim J, Ross JS. Direct-to-consumer broadcast advertisements for pharmaceuticals: off-label promotion and adherence to FDA guidelines. J Gen Intern Med. 2018;33(5):651–8.CrossRef Klara K, Kim J, Ross JS. Direct-to-consumer broadcast advertisements for pharmaceuticals: off-label promotion and adherence to FDA guidelines. J Gen Intern Med. 2018;33(5):651–8.CrossRef
4.
go back to reference Office of Inspector General. Advisory Opinion No. 10–07. U.S. Department of Health and Human Services web site. http://oig.hhs.gov/fraud/docs/advisoryopinions/2010/AdvOpn10-07.pdf (“For a patient to qualify for assistance under the Proposed Arrangement, the Specialty Medication must have been prescribed as part of an approved course of treatment for a specified disease, and must not be for an off- label use.”) Accessed August 8, 2019. Office of Inspector General. Advisory Opinion No. 10–07. U.S. Department of Health and Human Services web site. http://​oig.​hhs.​gov/​fraud/​docs/​advisoryopinions​/​2010/​AdvOpn10-07.​pdf (“For a patient to qualify for assistance under the Proposed Arrangement, the Specialty Medication must have been prescribed as part of an approved course of treatment for a specified disease, and must not be for an off- label use.”) Accessed August 8, 2019.
Metadata
Title
Off-Label Coverage of High-Cost Drugs by Independent Charity Patient Assistance Programs
Authors
So-Yeon Kang, MPH, MBA
Mariana P. Socal, MD, PhD
Ge Bai, PhD, CPA
Gerard F. Anderson, PhD
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 2/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05682-9

Other articles of this Issue 2/2021

Journal of General Internal Medicine 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine